Advisory Board and Editors Oncology
Daniela Brünnert
My current research is related to autoimmune diseases, where we develop and express and characterize specific AIM biologicals as tools against diseases like Type 1 diabetes, Multiple Sclerosis, NMO, and Parkinson's disease. Apart from that, I am interested in the development of novel cancer therapies with a particular focus on Multiple Myeloma, but also investigating other solid tumors. And a last major interest is related to pregnancy and understanding more about the role of Thrombin in terms of cytokine regulation and its functional consequences for trophoblast cells.
Tanya Amanda Camacho-Villegas
Tanya Camacho-Villegas is a Researcher for Mexico in the Medical and Pharmaceutical Biotechnology Unit, CIATEJ, A.C., located in Guadalajara, Jalisco, Mexico (2014-present). She is a member of the Mexican National System of Researchers level I. She works in recombinant protein design, cloning, and production (batch and bioreactor scale). She specializes in phage display for isolating single-domain antibodies such as vNAR´s or peptide isolation with diagnostic applications. Recently, she used the vNAR as an immuno-carrier for NPs for theranostics applications for breast cancer and glioblastomas as models.
She has received a BSc in Biology from the Science Faculty, UABC (2004) and a Marine Biotechnology MSc in CICESE (2007) focusing on the selection and validation of vNARs with anti-cytokines properties as candidates for TNFalpha and VEGF165 neutralizing in humans disorders.
She has received a PhD in Molecular Ecology and Biotechnology from the Marine Science Faculty at UABC (2012). She received a distinction in the Ph.D. dissertation
and fellowships from CONAHCYT for MSc, Ph.D., and Postdoc studies. She was the leader of four projects related to biotechnology companies. She was the author of patents related to vNAR as anti-cytokines or immuno-carriers for drug delivery.
Simone Cesaro
Graduated in Medicine in 1988 at the University of Padua. Pediatrician in 1992. I have been actively involved in pediatric hematology and oncology, especially in chemotherapy for leukemia and lymphoma, supportive care, and early and late effects of treatment, and hematopoietic stem cell transplantation (HSCT).
Appointed in 2009 Director of the Pediatric Hematology and Oncology Unit at the Department of Pediatrics in Verona. Member of the scientific committees of several working groups including Pediatrics (for MASCC), Supportive Care (for SIOP), Aplastic Anemia, Infection (for EBMT), hematopoietic stem cell transplant, Infection, Supportive care (for AIEOP). Appointed in 2005 and 2015 Chairman of the Supportive Care Group and Infection of AIEOP (Italian Association of Pediatric Hematology Oncology), respectively. Appointed in 2010, Chairman of Infectious Diseases Working Party of European Society for Blood and Marrow Transplantation.
Author of more than 200 publications in peer-reviewed journals. Medical advisor of the charities Paul O’Gorman Lifeline (UK) and Lifeline Italia, liaising with and advising pediatric hematology and oncology centers in Russia, Ukraine, Georgia and Kyrgyzstan.
Daniele Filippo Condorelli
Degrees M.D.: University of Catania (Italy), 1974-1980. Specialist in Neurology: University of Catania, 1980-1984. Ph.D. in Medical Biochemistry and Biology: University of Bari and Catania, 1984-1986.
Professional positions: 2001- today: Full professor of Biochemistry, School of Medicine, University of Catania; 1988-2000: Associate Professor of Biochemistry, University of Catania;. 2005-2009: Director of the School of Clinical Biochemistry; 2007-2013 coordinator of the PhD School in Translational Biomedicine.
Scientific publications.
1981-2018: 134 scientific papers in international peer-reviewed journal and 25 book chapters. Citations (years 1985-2018): 4612; without self-citations: 4367 (Web of Science, ISI); h-index 40
Research training abroad: 1983: Research associate at the MRC Developmental Neurobiology Unit. London (Dir.: Prof. R. Balazs); 1989-1990: Research associate at the Neurobiochemistry Group of the Mental Retardation Center, UCLA, Los Angeles (Dir.: Prof J. De Vellis)
Research interests: Neurotransmitter and neurotrophin receptors in glial cells; structure and expression of the glial fibrillary acidic gene; molecular biology of neuronal connexins; Experimental therapy of glioma tumors; Cancer genomics; Transcriptomics.
Council of International Scientific Societies:
2000-2004: elected member of the Council of the International Society for Developmental Neuroscience. 2007-2011: elected member of the Council of the International Society for Neurochemistry.
Thomas P. Conrads
Professor of Molecular & Cellular Biology and Obstetrics & Gynecology and Chief Scientific Officer of the Department of Defense-Funded Gynecologic Cancer Center of Excellence and the Women's Health Integrated Research Center at Inova Health System.
Christopher Cooper
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Subrata Deb
Dr. Subrata Deb is Chair & Associate Professor in the Department of Pharmaceutical Sciences at Larkin University, United States. Previous to this, he held positions at the Roosevelt University, The University of British Columbia and Tripura University.
Dr. Deb received his Bachelor of Pharmacy degree from the Berhampur University and his Master of Pharmaceutical Sciences from the University of Mumbai. He received his Ph.D. in Pharmaceutical Sciences from The University of British Columbia and subsequently completed his postdoctoral fellowship from the Vancouver Prostate Centre, a National Centre of Excellence.
Dr. Deb’s primary research interests include Pharmacology, Toxicology, Pharmacogenomics, and Pharmacokinetics with special emphasis on Drug Metabolism and Drug Interactions.
Carminia Maria Della Corte
-09/01/2018-current: Postdoc researcher at MDACC, Houston, Thoracic Head and Neck department, PI: Lauren Byers
-05/07/2012 – 04/07/2017: Residency in Medical Oncology (50/50 cum laude) at Second University of Naples, research thesis in:“Role of Hedgehog pathway in the acquisition of resistance to EGFR inhibitors in EGFR mutant non small cell lung cancer models”
- 10/10/2011: Degree in Medicine (110/110 cum laude), at Second University of Naples, research thesis in “Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors”
-Multiple first-name and co-authored publications in Transnational research in Oncology field.
Elaine A Dunlop
Dr. Elaine Dunlop is a Lecturer in the Division of Cancer and Genetics at Cardiff University. She received her PhD in Cancer Research from Queen's University, Belfast and her research now centres on the inherited genetic conditions, Tuberous Sclerosis Complex and Birt-Hogg-Dubé syndrome where patients are predisposed to develop cysts and tumours. She is interested in the crossover between the cell signalling observed in these genetic diseases and the pathways which are at fault in cancer, with a focus on mTORC1 growth pathways, autophagy and the tumour microenvironment.
Khalid El Bairi
Khalid El Bairi is the founder of The Cancer Biomarkers Working Group, and he is currently pursuing clinical and translational research in medical oncology. He has published many peer-reviewed articles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of the board of various international scientific societies such as the International Gynecologic Cancer Society (IGCS), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for more than 40 journals including BMC Cancer, PLoS ONE and Frontiers in Oncology and a guest editor for several special issues on gynecological cancers including Seminars in Cancer Biology and Current Drug Targets. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and Ph.D students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist.
Anthony C Faber
I currently serve as the co-leader of the developmental therapeutics program at VCU Massey Cancer Center, where I am also Associate Professor in the VCU Philips Institute. My laboratory focuses on finding new therapies in pediatric cancers.
Sherif Ashraf Fahmy
Dr. Sherif Ashraf Fahmy obtained his B. Pharm with honors from the Faculty of Pharmacy, Cairo University, and his MSc (2015) and Ph. D. (2020) in Chemistry from The American University in Cairo. His Ph. D. was conducted in collaboration with the Department of Pharmaceutics & Biopharmaceutics, Faculty of Pharmacy, Philipps-Universität Marburg, Germany. Dr. Fahmy was selected as one of the first recipients of the prestigious and very competitive fellowship offered by the Alfi Foundation for Ph.D. students. He has also spent time as a Visiting Scholar at the Department of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, Philipps University of Marburg, Germany, in 2018.
He has received several other awards and recognitions, most notably, the Royal Society of Chemistry (RSC, UK) Travel Grant for Ph.D. students & Early Career Scientists in 2019, the Fulbright Scholarship at Ohio University in 2019, USA, and the Mobility Grant to participate in the Research Opportunity Week (ROW) organized by the Technical University of Munich in 2022. Dr. Fahmy has published several peer-reviewed articles in international journals and many abstracts at local and international conferences (H- index of 15). Dr. Fahmy’s research focuses on exploring novel herbal medicine, extracting and characterizing their major active ingredients, and investigating their anticancer activities. In addition, Dr. Fahmy’s research encompasses the design, physicochemical characterization, and biological evaluation of innovative targeted and functionalized drug delivery systems to treat cancer effectively. These systems are based on several nanomaterials, including but not limited to polymeric nanoparticles, naovesicles (niosomes, liposomes, bilosomes, etc.), supramolecular nanocontainers (calixarenes, cucurbiturils, cyclodextrins), and metallic nanoparticles.
Also, Dr. Fahmy is a member of the Royal Society of Chemistry (MRSC), the American Chemical Society (ACS), and ESMO. Also, he serves as a reviewer for many international journals. Dr. Fahmy is a full-time Assistant Professor of Chemistry at the School of Life & Medical Sciences, University of Hertfordshire, Egypt Campus. Also, he is the Head and Founder of the Herbal Medicine & Nanotherapeutics research group at the same university.